Cactus Life Sciences Top 5 Trends of 2024

Cactus Life Sciences’ Top 5 Trends of 2024: Insights Driving Tomorrow’s MedComms

Here, we revisit our most thought-provoking articles and whitepapers, each addressing pivotal trends that influence the ever-evolving biopharma landscape...
Read More

Top Stories

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Involve Medical Affairs in insight management, early phases of clinical trials, etc.

It’s Never Too Soon: How and When to

Engagement with Medical Affairs is critical at every...
Leverage Social Media to Transform Medical Affairs | Promoting Disease Awareness, Ensuring Compliance and Assessing Outcomes

Leveraging Social Media to Transform Medical

This whitepaper explores the role of social media in...
Image - Understanding Patient Centricity, Progress Made, and Barriers Encountered Survey Questionnaire and Responses

Survey Report: Understanding Patient Centricity, Progress Made, and Barriers Encountered (Survey Questionnaire and Responses)

Cactus Communications commissioned a survey of pharma/biotech and associated industry professionals to understand the progress...

From Transactional to Transformational: Bringing Patient Centricity to the Next Level

The pharma industry’s focus is shifting from the transactional approach to a transformational approach by...
Plain Language Clinical Trial Summaries

Why Do Plain Language Clinical Trial Summaries Matter?

Did you know that the European Medicines Agency’s Clinical Trials Regulation comes into effect on...

MedTech Summit 2021: Understanding Post Market Clinical Follow Up (PCMF)

An ideal PMCF plan, with reference to MDCG 2020-7, presents the general and specific methods...

Bringing New Devices to Market under the EU MDR

With the MDR coming into effect, the manufacturers should plan and construct their strategy to...
Stakeholder perspectives on digital scientific content

Digital Scientific Content: Stakeholder Perspectives

What do the different relevant stakeholder groups truly expect from pharma-generated scientific content?...

Learn more ABOUT our company.